Skip to content

Effects of psilocybin with psychological support on anhedonia in treatment-resistant depression: A randomized controlled pilot trial.

Oct 2026 · Journal of Affective Disorders · pp. 122676 · 0 citations · 54 references
Medicine

TL;DR

Improvements on secondary measures suggest potential benefits for anhedonia and depression severity that warrant confirmation in larger trials.

Abstract

Background

Anhedonia is a core feature of major depressive disorder (MDD) that is frequently resistant to available treatments. Psilocybin's specific efficacy for anhedonia remains unclear.

Aims

To evaluate psilocybin's efficacy for anhedonia in treatment-resistant MDD.

Methods

In this randomized, double-blind, placebo-controlled trial, 20 participants with treatment-resistant MDD received psilocybin (25 mg or 1 mg) with psychological support. The primary outcome was change in the Dimensional Anhedonia Rating Scale (DARS) score at week 1; DARS change at week 8 was a secondary outcome. The Snaith-Hamilton Pleasure Scale (SHAPS) and Montgomery-Åsberg Depression Rating Scale (MADRS) were used as additional secondary outcome measures for anhedonia and overall depression severity, respectively.

Results

The primary outcome was not statistically significant: between-group difference in DARS change at week 1 was 11.2 (95% confidence interval [CI], -1.0 to 23.3; p = 0.073). At week 8, the secondary DARS outcome indicated greater improvement in anhedonia with 25 mg (difference, 14.7; 95% CI, 2.5 to 26.8; p = 0.018). SHAPS improvement favored 25 mg at week 1 (difference, -3.2; 95% CI, -6.1 to -0.3; p = 0.029), but not week 8 (-2.1; 95% CI, -4.9 to 0.9; p = 0.168). MADRS improvement favored 25 mg at weeks 1 (-11.9; 95% CI, -19.2 to -4.5; p = 0.002) and 8 (-11.6; 95% CI, -19.0 to -4.2; p = 0.002).

Conclusions

Psilocybin 25 mg did not significantly improve anhedonia at the primary week 1 endpoint. However, improvements on secondary measures suggest potential benefits for anhedonia and depression severity that warrant confirmation in larger trials. CLINICAL TRIAL REGISTRATION ClinicalTrials.govNCT06230757.

View source

Similar papers

Open access Oct 2026

Esketamine’s therapeutic effect on anhedonia in adolescents: a post-hoc of a randomized controlled trial

Anhedonia, a prominent symptom of major depressive disorder (MDD), severely impairs patients’ quality of life and is challenging to treat. Although esketamine has shown potential in treating anhedonia in adult treatment-resistant MDD, its effects on adolescents remain under-explored. In this study, a prosp...

Qian-Qian Wu, Wei-Cheng Li, Zhan-Jie Luo et al. · 0 citations
Review Open access Sep 2026

EFFICACY AND SAFETY OF PSILOCYBIN IN TREATMENT-RESISTANT DEPRESSION: A REVIEW

Major depressive disorder (MDD) is one of the leading causes of disability worldwide. A substantial proportion of patients fail to achieve remission through standard monoaminergic therapies, meeting the clinical criteria for treatment-resistant depression (TRD). TRD is associated with significant clinical morbidity and...

Mateusz Gawin, Emilia Koziara, Mateusz Gadzina et al. · 0 citations
Clinical trial Sep 2026

An Open-Label, Dose-Escalation Trial of Psilocybin-Assisted Therapy for Bipolar II Depression.

It is suggested that psilocybin therapy may be safe, tolerable, and preliminarily efficacious for treating depression in BD-II, but randomized controlled trials are needed to confirm efficacy and optimize protocols.

Amanda E. Downey, B. Szigeti, Ellen R. Bradley et al. · 0 citations
Review Open access Oct 2026

Psilocybin for anhedonia in unipolar and bipolar depression: A systematic review of clinical and preclinical evidence.

BACKGROUND Anhedonia is a debilitating core feature of mood disorders, and is associated with significant functional impairment and poor quality of life. Psilocybin has recently emerged as a novel antidepressant treatment in major depressive disorder (MDD), however, its effects on anhedonia specifically have yet to be...

Erica S. Kaczmarek, Sabrina Wong, Noah Chisamore et al. · 0 citations
Clinical trial Sep 2026

Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder and Anxious Distress: Post Hoc Analysis of a Phase 3, Randomized, Double-Blind Trial.

Objective: Anxious distress is associated with poor outcomes in the treatment of major depressive disorder (MDD). This exploratory post hoc analysis utilized data from a phase 3 study to investigate adjunctive lumateperone 42 mg efficacy in patients with MDD with inadequate antidepressant therapy (ADT) response and anx...

Gary S. Sachs, S. Durgam, W. Earley et al. · 0 citations
Open access Oct 2026

Psilocybin, cognitive stability and drinking reduction in co-occurring alcohol use disorder and depression: a pilot secondary analysis of a randomized, placebo-controlled trial

Background. Change in cognitive control is a candidate transdiagnostic mechanism of psychedelic therapy. One account predicts that, once acute effects resolve, psilocybin shifts control toward flexibility while sparing inhibition and working memory. A motivational account (PRISM) predicts that psilocybin increases the...

C. Sayali, E. Weisman, F. Barrett · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.